Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by ethnicity and race: ONWARDS 1-5

被引：0
|
作者：
Lingvay, I. [1 ,2 ]
Bangsgaard, K. O. [3 ]
Desouza, C. [4 ]
Fragao-Marques, M. [3 ]
Navarria, A. [3 ]
Vianna, A. [5 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Endocrinol, Dallas, TX USA
[2] Univ Texas Southwestern Med Ctr Dallas, Peter ODonnell Jr Sch Publ Hlth, Dallas, TX 75390 USA
[3] Novo Nordisk AS, Soborg, Denmark
[4] Univ Nebraska Med Ctr, Omaha, NE USA
[5] Hosp Nossa Senhora Gracas, Curitiba Diabet Ctr, Dept Endocrine Dis, Curitiba, Parana, Brazil
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
785
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [31] No evidence of increased hypoglycaemia attributed to physical activity with once-weekly insulin icodec versus once-daily basal insulin degludec in type 1 diabetes: A post hoc analysis of ONWARDS 6
    Sourij, Harald
    Bracken, Richard M.
    Carstensen, Lisbeth
    Rocha, Thais M. Pagliaro
    Watt, Sara Kehlet
    Philis-Tsimikas, Athena
    DIABETES OBESITY & METABOLISM, 2025,
  • [32] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with Type 2 diabetes (SUSTAIN 4)
    Aroda, V. R.
    Bain, S. C.
    Cariou, B.
    Piletic, M.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    de Vries, J. H.
    DIABETIC MEDICINE, 2017, 34 : 146 - 146
  • [33] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    DeVries, J. H.
    Bain, S. C.
    Cariou, B.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    Aroda, V. R.
    DIABETOLOGIA, 2016, 59 : S76 - S77
  • [34] Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management
    Goldman, Jennifer
    Triplitt, Curtis
    Isaacs, Diana
    ANNALS OF PHARMACOTHERAPY, 2024,
  • [35] CGM in insulin-experienced individuals with type 2 diabetes switched to once-weekly insulin icodec versus once-daily comparators in ONWARDS 2 and 4: post hoc analysis
    Asbjornsdottir, B.
    Bajaj, H. S.
    Lehrskov, L. L.
    Mathieu, C.
    Philis-Tsimikas, A.
    Wang, N.
    Battelino, T.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S398 - S398
  • [36] Superior Glycemic Control with Once-Weekly Insulin Icodec with a Dosing Guide App vs. Once-Daily (OD) Basal Insulin Analogs in Insulin-Naive T2D-ONWARDS 5
    Bajaj, Harpreet S.
    Aberle, Jens
    Davies, Melanie J.
    Donatsky, Anders M.
    Frederiksen, Marie
    Yavuz, Dilek Gogas
    Gowda, Amoolya
    Lingvay, Ildiko
    Bode, Bruce W.
    DIABETES, 2023, 72
  • [37] Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1
    Polonsky, William
    Benamar, Malik
    Carstensen, Lisbeth
    Davies, Melanie
    Donatsky, Anders Meller
    Franek, Edward
    Kellerer, Monika
    Philis-Tsimikas, Athena
    Goldenberg, Ronald
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 217
  • [38] Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China
    Hu, Shanshan
    Wang, Shuowen
    Gu, Shengying
    Qi, Chendong
    Shi, Chenyang
    Fan, Guorong
    DIABETES OBESITY & METABOLISM, 2024,
  • [39] Cost-utility analysis of once-weekly insulin icodec and once-daily insulin glargine in patients with type 2 diabetes receiving basal-bolus insulin therapy in China
    Dai, Nan
    Su, Xiaorong
    Wang, Yong
    DIABETES OBESITY & METABOLISM, 2025, 27 (01): : 377 - 386
  • [40] CGM outcomes and hypoglycaemia duration with once-weekly insulin icodec versus once-daily insulin glargine u100 in insulin-naive type 2 diabetes: ONWARDS 1 exploratory analysis
    Bergenstal, R.
    Watt, S. Kehlet
    Matos, A. S. A.
    Lingvay, I.
    Mader, J. K.
    Nishida, T.
    Rosenstock, J.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S397 - S397
12345